Mark Jason Heath Ellison Opiant Pharmaceuticals, Inc. (OPNT) insider trading activity

Mark Jason Heath Ellison is Chief Development Officer of OPIANT PHARMACEUTICALS, INC.. Currently has a direct ownership of 0 shares of OPNT, which is worth approximately $0. The most recent transaction as insider was on Mar 02, 2023, when has been sold 20,751 shares (Common Stock) at a price of $20.0 per share, resulting in proceeds of $415,020. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Mark Jason Heath Ellison Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 02 2023	SELL Sale (or disposition) back to the issuer	$415,020 $20.0 p/Share	20,751 Reduced 100.0%	0 Common Stock
Mar 02 2023	BUY Grant, award, or other acquisition	-	2,000 Added 50.0%	2,000 Common Stock
Jan 27 2023	SELL Open market or private sale	$12,358 $20.26 p/Share	610 Reduced 3.15%	18,751 Common Stock
Jan 09 2023	SELL Open market or private sale	$9,473 $20.2 p/Share	469 Reduced 2.37%	19,361 Common Stock
Jan 05 2023	SELL Open market or private sale	$36,481 $20.2 p/Share	1,806 Reduced 8.35%	19,830 Common Stock
Jun 27 2022	BUY Grant, award, or other acquisition	-	2,000 Added 8.46%	21,636 Common Stock
Jan 04 2022	BUY Grant, award, or other acquisition	-	12,000 Added 37.93%	19,636 Common Stock
Jan 26 2021	BUY Grant, award, or other acquisition	-	7,636 Added 50.0%	7,636 Common Stock

MJH

Mark Jason Heath Ellison

Chief Development Officer

Santa Monica, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells OPNT shares.

Notify only if

Value

Insider Trading

Get notified when an Opiant Pharmaceuticals, Inc. insider buys or sells OPNT shares.

Notify only if

Operation

Value

Type

News

Receive news related to OPIANT PHARMACEUTICALS, INC.

Track Activities on OPNT

Account